A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

February 8, 2024

Study Completion Date

February 8, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin icodec

Participants will receive subcutaneously fixed dose of insulin icodec (700 U/mL) that is 5.6 U/kg bodyweight.

Trial Locations (13)

14203

UBMD Peds-Div of Endo/Diabetes, Buffalo

21287

John Hopkins Univ Hosp, Baltimore

22908

University of Virginia Clinical Research Unit, Charlottesville

University of Virginia, Charlottesville

32207

Nemours Children's Health, Jacksonville

Nemours Chld Clnc Jacksonville, Jacksonville

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Child's Hsp Med Ctr, Cincinnati

70808

Pennington Biom Res Ctr, Baton Rouge

90027

Children's Hosp-Los Angeles, Los Angeles

Children's Hospital Los Angeles - Endocrinology, Los Angeles

06510

Yale New Haven Hospital, Hospital Research Unit, New Haven

06511

Yale University, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY